Prof. Dr.Erkan Doğan

  • İlgi Alanları
  • Meme kanseri
  • Akciğer kanseri
  • Kolon kanseri
  • Özefagus kanseri
  • Mide kanseri
  • Jinekolojik kanserler
  • Nadir kanserler
  • Hepatoselüller kanser

Eğitim ve Uzmanlık
1998 – Marmara Üniversitesi Tıp Fakültesi  (İngilizce)– Tıp eğitimi
2004 – Taksim Eğitim ve Araştırma Hastanesi – İç Hastalıkları Uzmanlık Eğitimi
2011 – Hacettepe  Üniversitesi Tıp Fakültesi – Tıbbi Onkoloji Uzmanlık Eğitimi

Deneyim
2004-2007 - Ağrı Patnos Devlet Hastanesi, Uzman Doktor İç Hastalıkları
2007-2008 - Yüzüncü Yıl Üniversitesi Tıp Fakültesi, İç Hastalıkları AD Yrd. Doç.
2008-2011- Hacettepe Üniversitesi Tıp Fakültesi, Tibbi Onkoloji Uzmanlık Eğitimi
2011-2013 - Van Bölge Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Bölümü
2013-2017 - Van YYÜ Tıp Fakültesi İç Hastalıkları AB Tıbbi Onkoloji BD
2017-2021 - İstanbul Yeni Yüzyıl Üniversitesi Tıp Fakültesi Gaziosmanpaşa Hastanesi Tıbbi Onkoloji Bölümü

Kurs ve Sertifikalar
ESMO Kursu:
Essentials of Medical Oncology, 26-30 November 2008, İstanbul
AKADEMİKA Klinik Araştırmalarda Doğru Uygulama Esasları Paylaşım Programı, 13-15 Kasım 2009, İstanbul, Türkiye
ESMO Kursu: Essentials Of Medical Oncology. 3. Tıbbi Onkoloji Güncelleme Kursu. February 3-7, 2010, İstanbul, Türkiye
Course On Conducting A Trial According To Good Clinical Practice (GCP), 04 April 2011, Milan, İtaly
YER ALDIĞI ULUSLARARASI KLİNİK ARAŞTIRMALAR:
Uluslararası İNVEST çalışmasında yardımcı araştırmacı olarak yer almak
Uluslararası Cariatide çalışmasında yardımcı araştırmacı olarak yer almak
Uluslararası ATHENA çalışmasında yardımcı araştırmacı olarak yer almak
Ulusal ERADA çalışmasında yardımcı araştırmacı olarak yer almak
Uluslar arası TİDE 13-14 çalışmasında sorumlu araştırmacı olarak yer almak
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer, yardımcı araştırmacı
Tide 13-14, Observational phase IV study, sorumlu araştırmacı
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, sorumlu araştırmacı.

Mesleki Üyelikler
Türk Tabipler Birliği
Türk Tıbbi Onkoloji Derneği
ESMO, European Society for Medical Oncology

A. Uluslararası hakemli dergilerde yayımlanan makaleler:

  1. .Erkan Doğan, H.Yorgun, I.Petekkaya, N.Ozer, K.Altundag, Y.Ozisik. Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience. Med Oncol. 2012;1-8 DOI: 10.1007/s12032-012-0253-5

2.Erkan Doğan, S.Yalcin, D.Koca, A.Olmez Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2012;13:2985-90

3. C.Arslan, E.Ozdemir, Erkan Doğan, Y.Ozisik, K.Altundag. Secondary hematological malignancies after treatment of non-metastatic breast cancer. J BUON. 2011;16:744-50.

4. Erkan Doğan, S.Aksoy, O.Dizdar, C.Arslan, DS.Dede, Y.Ozisik, K.Altundag. Pure mucinous carcinoma of the breast: a single center experience. J BUON. 2011;16:565-7

5. N.Bulut, S.Aksoy, O.Dizdar, DS.Dede, C.Arslan, E.Dogan, I.Gullu, Y.Ozisik, K.Altundag. Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Med Oncol. 2011;28:S75-9.

6.Erkan Doğan, O.Maviş, N.Turan, H.Demir, M.İlhan. The relationship between lipoprotein (a) levels and microvascular complications in patients with type 2 Diabetes mellitus. Oriental Journal of Chemistry.2010;26: 361-367.

7.D.Turgut, I.Kalan, DS.Dede, Erkan Doğan, K.Altundag. Ipsilateral axillary recurrence of breast cancer 22 years after primary surgery: the latest recurrence in the literature. J BUON. 2011;16:571.

8. O.Kara, E.Ozdemir, C.Arslan, Erkan Doğan, K.Altundag. Acute promyelocytic leukemia in a young patient with breast cancer. Med Oncol. 2011;28:249-50.

9.Z.Arik, Erkan Doğan, S.Aksoy, K.Altundag. Long-term survivors among breast cancer patients with brain metastases. Ann Oncol. 2010;21:1128.

10.Erkan Doğan, S.Aksoy, O.Dizdar, DS.Dede, C.Arslan, Y.Ozisik, K.Altundag. Other malignancies in patients with breast cancer: a single institute experience. Med Oncol. 2010 Dec;27(4):1434-5.

11.Erkan Doğan, S.Aksoy, C.Arslan, DS.Dede, K.Altundag. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol. 2010;27: 1436-7.

12.E.Altan, C.Arslan, D.Dede, Erkan Doğan, K.Altundag. Primary angiosarcoma of the breast after pregnancy. Am Surg. 2010;76:E115.

13.N.Kertmen, Erkan Doğan, K.Altundag. Pure mucinous breast carcinoma with lung metastasis in a young male patient. Am Surg. 2010;76:E146.

14.D.Sarikaya, O.Varan, G.Ozen, Erkan Doğan, K.Altundag. Late recurrence of granulosa cell tumor of the ovary with synchronous gastric signet-ring cell carcinoma. J BUON .2010; 15: 799-800.

15.O.Varan, G.Ozen, D.Sarikaya, Erkan Doğan, K.Altundag. Malignant hypercalcemia in a patient with maxillary sinus squamous cell carcinoma without skeletal metastases. Am Surg. 2010;76:E9-10.

16.E.Altan, B.Bitik, Y.Kalpakci, Erkan Doğan, K.Altundag. Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee. J Altern Complement Med. 2009;15:113.

17.B.Bitik, Y.Kalpakci, E.Altan, Erkan Doğan, K.Altundag. Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen. Ann Oncol. 2009;20:394-5.

18. Erkan Doğan, R.Ozgür, V.Ercan, A.Tekin, O.Senkal, U.Cevikbaş. Nodular regenerativehyperplasia of the liver: a case report. Turk J Gastroenterol. 2003;14:64-7

19. Koca D, Doğan Erkan, Yardim H, Duzen O, Karaca S. A modified DCF regimen as primary  treatment for patients with metastatic gastric cancer. J BUON. 2013 Apr-Jun;18(2):377-84

20. O.Emre, H.Demir, Erkan Doğan, R.Esen, T.Gur, C.Demir, E.Gonullu, N.Turan, M.F.Özbay. Plasma Concentrations of Some Trace Element and Heavy Metals in Patients with Metastatic Colon Cancer. Journal of Cancer Therapy, 2013, 4, 1085-1090

21. Sunnetcioglu A, Arısoy A, Demir Y, Ekin S, Doğan Erkan. Associations between the standardized uptake value of (18)F-FDG PET/CT and demographic, clinical, pathological, radiological factors in lung cancer. Int J Clin Exp Med. 2015 Sep 15;8(9):15794-800.

22. Turan N, Benekli M, Unal OU, Unek İT, Tastekin D, Dane F, Algın E, Ulger S, Eren T, Topcu TO, Turkmen E, Babacan NA, Tufan G, Urakci Z, Ustaalioglu BO, UysalOS, Ercelep OB, Taskoylu BY, Aksoy A, Canhoroz M, Demirci U, Doğan Erkan, Berk V, Balakan O, Ekinci AŞ, Uysal M, Petekkaya İ, Ozturk SC, Tonyalı Ö, Çetin B, Aldemir MN, Helvacı K, Ozdemir N, Oztop İ, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chin J Cancer Res. 2015 Aug;27(4):408-16.

23. Petekkaya I, Aksoy S, Roach EC, Okoh AK, Gecmez G, Gezgen G, Isler DC, Doğan Erkan, Babacan T, Sarici F, Petekkaya E, Altundag K. Impact of inflammatory markers on the prognosis of patients with operable breast cancer. J BUON. 2014 Jul-Sep;19(3):673-80.

24. Turan N, Benekli M, Dane F, Unal OU, Kara HV, Koca D, Balvan O, Eren T, Tastekin D, Helvaci K, Berk V, Demirci U, Ozturk SC, Doğan Erkan, Cetin B, Kucukoner M, Tonyali O, Tufan G, Oztop I, Gumus M, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thorac Cancer. 2014 Sep;5(5):398-404.

25. Can A, Doğan Erkan, Bayoglu IV, Tatli AM, Besiroglu M, Kocer M, Dulger AC, Uyeturk U, Kivrak D, Orakci Z, Bal O, Kacan T, Olmez S, Turan N, Ozbay MF, Alacacioglu A. Multicenter epidemiologic study on hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2014;15(6):2923-7.

26. Turan N, Benekli M, Unal OU, Unek İT, Tastekin D, Dane F, Algın E, Ulger S, Eren T, Topcu TO, Turkmen E, Babacan NA, Tufan G, Urakci Z, Ustaalioglu BO, UysalOS, Ercelep OB, Taskoylu BY, Aksoy A, Canhoroz M, Demirci U, Doğan Erkan, Berk V, Balakan O, Ekinci AŞ, Uysal M, Petekkaya İ, Ozturk SC, Tonyalı Ö, Çetin B, Aldemir MN, Helvacı K, Ozdemir N, Oztop İ, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chin J Cancer Res. 2015 Aug;27(4):408-16.

27. Arslan H, Fatih Özbay M, Çallı İ, Doğan Erkan, Çelik S, Batur A, Bora A, Yavuz A, Bulut MD, Özgökçe M, Çetin Kotan M. Contribution of diffusion weighted MRI to diagnosis and staging in gastric tumors and comparison with multi-detector computed tomography. Radiol Oncol. 2017 Feb; 51: 23-

B.Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler:

1.Erkan Doğan, H.Yorgun, I.Petekkaya, N.Ozer, K.Altundag, Y.Ozisik. Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience. 2011 ASCO, Annual meeting Nisan, 2011 Şikago, ABD, (Sözel Bildiri).

2.Ö.Keskin, C.Arslan, O.Dizdar, S.Aksoy, Erkan Doğan, D.S.Dede, I.H.Gullu, Y.Y. Ozisik, K.Altundag. Relation of tumor localization and metastasis sites in patients with breast cancer, ASCO 2011, Şikago, ABD.

3.D.S.Dede, C.Arslan, S.Aksoy, O.Dizdar, Erkan Doğan, A.Alkan, I.H.Gullu, Y.Y.Özisik, K.Altudag. Clinicopathologic features of patients with breast cancer under teatment of bisphosphonate at the time of diagnosis: Retrospective analysis, ASCO 2011. Şikago, ABD.

4.I.Petekkaya, C.Arslan, Erkan Doğan, M.Solak, Ö.Keskin, N.Kertmen, Y.Y.Özisik, K.Altundag. Body mass index in breast cancer subtypes, ASCO 2011. Şikago, ABD.

5.M.Solak, F.P.Turkoz, I.Petekkaya, C.Arslan, N.Kertmen, Ö.Keskin, Erkan Doğan, Y.Y.Özisik, M.K.Altundag. Association between blood groups and breast cancer subtype, ASCO 2011. Şikago, ABD.

6.M.Ozen, S.Aksoy, O.Dizdar, D.S.Dede, Erkan Doğan, C.Arslan, I.H.Gullu, M.K.Altundag. Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis, ASCO 2010.Şikago, ABD.

7.Z.G.Sürmeli, S.Aksoy, O.Dizdar, D.S.Dede, Erkan Doğan, C.Arslan, I.H.Gullu, K.Altundag. Docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy for operable HER2-negative, node-positive breast cancer patients: Results from a single institution, ASCO 2010. Şikago, ABD.

8.S.Aksoy, C.Arslan, M.Kurt, O.Dizdar, D.S.Dede, Erkan Doğan, I.H.Gullu, Y.Y.Ozisik, M.K.Guler. Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit?, ASCO 2010, Şikago, ABD.

9.C.Arslan, O.Dizdar, D.S.Dede, M.Isik, Erkan Doğan, Y.Y.Özisik, K.Altundag. Clinicopathological features of locally advanced HER2-negative breast cancer patients with stage N3 disease, ASCO 2011. Şikago, ABD.

10.S.Aksoy, N.Bulut, Ö.Dizdar, D.Dede, C.Arslan, Erkan Doğan, Y.Özışık, K.Altudag. Demographic, clinical and pathological characteristics of very young (younger than 30 years) breast cancer patients in Turkish population. 5th İnternational APOCP Conferense, 2010, İstanbul, Türkiye.

11. H.Arslan, M.F.Özbay, I.Çallı, Erkan Doğan, Dffüzyon Ağırlıklı, Magnetik Rezonans Görüntülemenin Mide tümörlerinde tanı ve evrelemeye katkısı. 3rd İnternational Gastrointestinal Cancer Conference, Aralık 2013, Antalya. (Sözel Bildiri)

12. A.Can, Erkan Doğan, İ.V.Bayoğlu, A.M.Tatlı, M.Beşiroğlu, M.Koçer, Ü.Üyetürk, D.Kıvrak, Z.Orakçı, ÖBal, T.Kaçan, N.Turan. Epidemiology of hepatocellular carcinoma ın Turkey. Outcome of multicenter study. 3rd İnternational Gastrointestinal Cancer Conference, Aralık 2013, Antalya (Sözel bildiri)

13. Erkan Doğan, A.Can, M.F.Özbay, H.Arslan, G.Yılmazer, D.Koca, Ç.Kotan. Clinicopathological characteristics of esophageal cancer patients of Van region. 3rd İnternational Gastrointestinal Cancer Conference, Aralık 2013, Antalya.

14. Erkan Doğan, H.Güdücüoğlu, A.Can, R.Erten, S.Koç, Y.Bayram. Human papıllomavırus and survival of patients with esophageal squamous cell cancers. 3rd İnternational Gastrointestinal Cancer Conference, Aralık 2013, Antalya.

15. Ö.Emre, H.Demir, Erkan Doğan, R.Esen, T.Gür, C.Demir, E.Gönülü, N.Turan, N.Mert: İnvestigation of Some Trace Element and Heavy Metal Concentrations In Patients With Colon Cancer. 2nd İnternational Gastrointestinal Cancer Conference, December 14-16, 2012 İstanbul.

D.Ulusal hakemli dergilerde yayımlanan makaleler:

1. Erkan Doğan, S.Kılıçkap, İ.Çelik. Kemoprevansiyonda Kullanılan Yeni İlaçlar. Review.Turkiye Klinikleri J Med Oncol-Special Topics. 2009;73-82.

2. Celik S, Doğan Erkan, Arslan H, Batur A, Kiziltan R, Toktas O, Yilmaz O, Kotan M. C. Changing Trends and Experience with Esophageal Cancer Surgery in a Single University Hospital: Are The Results Similar or Not? Bagcilar Medical Bulletin 2017; 2 :1-8.